PolyPid Ltd. misses on earnings expectations. Reported EPS is $-0.41 EPS, expectations were $-0.34. Operator: Greetings and welcome to PolyPid’s Fourth Quarter and Full Year 2025 Conference Call.
1-Year Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate High Patient Survival with Low Morbidity 2-Year Data from the AMDS PERSEVERE IDE Trial Further Demonstrate the Persistent Clinical ...
New eTMF module integrates with Enlighten Clinical Solutions’ platform to support inspection-ready clinical trial documentation and execution. ATLANTA, GA, UNITED ...
ATLANTA, GA, UNITED STATES, January 13, 2026 / EINPresswire.com / — Enlighten Clinical Solutions today announced the official release of its integrated electronic Trial Master File (eTMF) module, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results